Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.07 | N/A | +14.37% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-3.07 | N/A | +14.37% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current market conditions impacting revenue. They remain focused on long-term strategies despite short-term setbacks.
Management acknowledged ongoing challenges in revenue generation.
They emphasized a focus on future product development and innovation.
Moderna's earnings report shows a significant EPS miss, but the stock reacted positively, rising 12.68%. This increase may reflect investor optimism about future product developments despite the current losses. The lack of revenue data and guidance suggests uncertainty in the near term, but the market seems willing to overlook these issues for now.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BANCO BILBAO VIZCAYA ADR
Apr 29, 2024